Community/Retail

Researchers will submit a new drug application to the FDA after a phase 3 trial found that iDose TR slow- and fast-release models met their primary endpoint in patients with glaucoma.

Pharmacists should get involved in all the various aspects of their business and with the different professional groups available.

GENDER R25 will provide funding for courses and curricula to improve gender-focused education and equity in pharmacy, as well as other health care fields.

The most important thing you must do is listen to the patient, understand their concerns, and by doing that, you will gain their trust to be able to treat them appropriately.

Pharmacists can educate older adults on risk factors and prevention efforts around herpes zoster.

Analytics allow for a better understanding of the needs of various patient populations and the barriers they face in accessing care.

USC Analysis: although generics save US health care systems billions, PBMs jack up prices for employers, government, and patients.

Quadrivalent mRNA influenza vaccine candidate to be evaluated in approximately 25,000 healthy US adults.

Migraines are multifactorial and patient-specific, causing accessible care and treatments to be limited and ignored.

Men with chronically low testosterone levels are more likely to be hospitalized from COVID-19 than those with normal levels, but testosterone therapy could decrease this risk.

Online communities can help opioid users in remission maintain long-lasting sobriety, however the research suggests these communities should be non-drug-related.

Care Coach program offers a comprehensive set of pharmacy and counseling services to patients struggling to manage their diabetes.

Simple steps to minimize risk are easily overlooked when pharmacies get busy.

Many drugs for these conditions enter clinical trials, but few demonstrate success.

DaxibotulinumtoxinA-lanm from Revance Therapeutics Inc is the first peptide-formulated neuromodulator with long-lasting results.

The drug improves kidney function in adults with hepatorenal syndrome with rapid reduction in kidney function.

Researchers found that patients diagnosed with early-onset type 2 diabetes have a greater risk of premature death than the general population.

Deucravacitinib is a selective, allosteric tyrosine kinase 2 (TYK2) inhibitor, which is a member of the Janus kinase (JAK) family.

Alopecia areata is an autoimmune disease with an underlying immuno-inflammatory pathogenesis.

Pharmacists should ascertain whether self-treatment is appropriate and suggest medical care if it isn’t.

Part A results from the 2-part LILAC study show that the therapy significantly reduced disease activity based on active joint count in individuals compared with the placebo.

Study suggests gene therapy may effectively treat young children who were born colorblind via pathways connecting the brain and the retina.

Research suggests that subcutaneous insulin aspart is a cost-effective and accessible treatment option that could allow children with type 1 diabetes to avoid the ICU after a mild episode of diabetic ketoacidosis.

The long-acting, once-daily hormone controls high blood sugar in individuals aged 1 year or older with diabetes.

Research indicates that poor technique or failure to follow up-to-date standards and protocols could lead to injury or even death of patients who need compounded medications.

Key responsibilities include providing recommendations, administering vaccinations, disseminating evidence-based advice, reducing spread of influenza in communities.

Excess drinking is a major atrial fibrillation risk factor in young people.

ADvocate 1 and ADvocate 2 are 52-week randomized, double-blind phase 3 studies designed to evaluate lebrikizumab as monotherapy in adult and adolescent patients with moderate to severe AD.

It is currently indicated for the treatment of adult patients with active psoriatic arthritis and adult patients with oral ulcers associated with Behçet's Disease.

The New Drug Application for aripiprazole 2-month, ready-to-use, long-acting injectable could lead to the first FDA approval of a 2-month schizophrenia and bipolar I disorder antipsychotic treatment.